Related Experiment Video

Updated: Jul 18, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure

Andrew E Ajani1, Thomas H Marwick, Henry Krum

  • 1Department of Cardiology, Royal Melbourne Hospital, and Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. andrew.ajani@mh.org.au

Cardiovascular Revascularization Medicine : Including Molecular Interventions
|December 19, 2006
PubMed

Insights

Selective aldosterone antagonist eplerenone reduces mortality in patients with heart failure after myocardial infarction. This review covers evidence and clinical implications for aldosterone antagonists in post-MI heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) following acute myocardial infarction (MI) presents a growing clinical challenge.
  • Aldosterone plays a key role in the pathophysiology of post-MI HF.

Purpose of the Study:

  • To review the evidence for the selective aldosterone antagonist eplerenone in patients with post-MI HF.
  • To discuss the clinical implications of aldosterone antagonists in this patient population.

Main Methods:

  • Review of clinical trial data and existing literature on eplerenone and aldosterone antagonists.
  • Analysis of mortality data in patients with post-MI HF treated with eplerenone versus placebo.

Main Results:

  • Eplerenone demonstrated a significant reduction in mortality compared to placebo in patients with post-MI HF.
  • Aldosterone blockade is a beneficial therapeutic strategy in this setting.

Conclusions:

  • Eplerenone offers significant survival benefits for patients with heart failure post-myocardial infarction.
  • Aldosterone antagonists represent an important therapeutic option for managing post-MI HF.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...